Area of research
Hematology · Molecular Biology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Amyloidosis: Diagnosis, Treatment, Outcomes, Chronic Lymphocytic Leukemia Research, and Lymphoma Diagnosis and Treatment.
Wild-Type Transthyretin-Related Amyloidosis in Kindreds: A Play of Chance or New Epiphenomenon?
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry.
An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapy.
Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosis.
A collaborative approach to amyloidosis and a multidisciplinary care framework - position statement from the International Society of Amyloidosis.
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.
Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Cardiac “hypertrophy” phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography
The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population.
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.
Cardiac "hypertrophy" phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography.
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia.
Safety, Feasibility, and Efficacy of Exercise Interventions for People With Multiple Myeloma: A Systematic Review.
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma.
Safety, Feasibility, and Acceptability of a Multisite Individualized Exercise Intervention for People with Multiple Myeloma.
Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.
Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma.
Screening for and diagnosis of monoclonal gammopathy.
PB2698: MORE EFFICIENT DELIVERY OF HIGH-COST STANDARD-OF-CARE THERAPIES IN RELAPSED MULTIPLE MYELOMA USING REAL-TIME FEEDBACK OF PATIENT-REPORTED OUTCOME MEASURES: THE MY-PROMPT-2 TRIAL
2023cited by 0position: contributor
P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL
2023cited by 0position: contributor
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Current approaches to the diagnosis and management of amyloidosis.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
An Individualized Exercise Intervention for People with Multiple Myeloma-Study Protocol of a Randomized Waitlist-Controlled Trial.